Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, 510 20th Street South, Faculty Office Tower 820D, Birmingham, AL, 35294, USA.
Curr Osteoporos Rep. 2018 Dec;16(6):738-745. doi: 10.1007/s11914-018-0487-z.
To examine the importance of recent fracture as a predictor of imminent fracture risk, review the importance of prior fracture type and timing, and identify risk factors for recurrent osteoporotic fracture.
Prior fracture type and timing impact risk of subsequent fracture that is largely independent of bone mineral density. Site of re-fracture is similar to original major osteoporotic fracture. Incidence of recurrent major osteoporotic fracture is greatest within the first year. Other risk factors include those that pertain to individual characteristics. Approved osteoporosis therapies reduce risk of recurrent fracture. Prior fracture timing, type, and individual characteristics are important components of predicting the risk of future fracture. Initiation of osteoporosis medication therapy should be started after initial fracture to reduce the risk of future fracture, though these medications typically take 6-12 months to have an effect, during which time is the highest rate of imminent re-fracture.
探讨近期骨折作为即将发生骨折风险的预测指标的重要性，回顾既往骨折类型和时间的重要性，并确定复发性骨质疏松性骨折的危险因素。
既往骨折类型和时间对后续骨折风险有重要影响，而这在很大程度上独立于骨密度。再骨折的部位与最初的主要骨质疏松性骨折相似。复发性主要骨质疏松性骨折的发生率在最初的 1 年内最高。其他危险因素包括与个体特征有关的因素。经批准的骨质疏松症治疗方法可降低复发性骨折的风险。既往骨折时间、类型和个体特征是预测未来骨折风险的重要组成部分。应在初次骨折后开始骨质疏松症药物治疗，以降低未来骨折的风险，尽管这些药物通常需要 6-12 个月才能起效，在此期间是再次骨折的最高风险期。
